The combination of cisplatin, gemcitabine, and gefitinib is well tolerated, and the addition of gefitinib does not appear to improve response rate or survival [39, 40]
Geftinib
31
6.5
Geftinib (ZD1839) is ineffective as a second-line agent for urothelial carcinoma [41]
EGFR and ErbB2 signaling
Lapatinib
59
ORR (1.7%) and SD (31%)
A negative result, but clinical benefit (ORR and SD) is correlated with EGFR overexpression (), and, to some extent, HER-2 overexpression [42]
EGFR, VEGFR, and RET signaling
Vandetanib plus docetaxel versus placebo plus docetaxel
142
ORR, 7 versus 11 (); PFS, 2.6 m versus 1.6 m (); OS, 5.9 m versus 7.0 m ()
The addition of vandetanib to docetaxel did not result in a significant improvement in PFS, ORR, or OS [43]